nach oben

Wiener klinische Wochenschrift

Erschienen in:

31.05.2021 | review article

New strategies in the management of valvular heart disease

A critical appraisal on the top 10 messages of the 2020 ACC/AHA guidelines for the management of patients with valvular heart disease

verfasst von: Gudrun Lamm, MD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 15-16/2021

Einloggen, um Zugang zu erhalten

Summary

The advent of transcatheter procedures for treatment of valvular heart disease has accelerated the pace of research in the diagnosis and treatment of heart valve disease. Rapid accumulation of novel knowledge in the field necessitates timely revisions of clinical guidelines. This paper comments on some important and novel issues addressed in the recently published American College of Cardiology/American Heart Association (ACC/AHA) guidelines.

Vorheriger Artikel Transcatheter treatment by valve-in-valve and valve-in-ring implantation for prosthetic tricuspid valve dysfunction

Nächster Artikel Effect of music on patients with cardiovascular diseases and during cardiovascular interventions

Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:e521–e643.PubMed

Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739–91.CrossRef

Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, et al. 2020 ACC/AHA Guideline for the Management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020; https://doi.org/10.1016/j.jacc.2020.11.018.CrossRefPubMedPubMedCentral

Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused up-date of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e1159–e95.CrossRef

Nijenhuis VJ, Brouwer J, Delewi R, et al. Anticoagulation with or without clopidogrel after transcatheter aortic valve implantation. N Engl J Med. 2020;382:1696–707.CrossRef

Titel: New strategies in the management of valvular heart disease
A critical appraisal on the top 10 messages of the 2020 ACC/AHA guidelines for the management of patients with valvular heart disease
verfasst von: Gudrun Lamm, MD
Publikationsdatum: 31.05.2021
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 15-16/2021
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-021-01879-y

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 15-16/2021

Utility of procalcitonin in a medical intensive care unit in Croatia

MUW researcher of the month

2020 update of the Austrian Society of Cardiology (ÖKG) and the Austrian Society of Cardiac Surgery (ÖGHTG) on the position statement of the ÖKG and ÖGHTG for transcatheter aortic valve implantation 2011

Beneficial effect of ACE inhibitors on kidney function in polycythemia vera

Considering additive effects of polypharmacy

Coronary angiography in patients after cardiac arrest without ST-elevation myocardial infarction